Developed Formulas
  • Supports resolution of mild to moderate acne

  • Reduces pro-inflammatory IL-8

  • Induces anti-inflammatory IL-10

  • Counteracts pathogenic C. acnes

  • Supports resolution of facial lesions, erythema and desquamation

  • Reduces sebum secretion

Ready to market
Clinical test
In vitro test
Allergen Free
Real time stability

Bifidobacterium breve BR03 (DSM 16604)
Ligilactobacillus salivarius LS03 (DSM 22776)
Lacticaseibacillus casei LC03(DSM 27537)

Label Claim
Effective nutraceutical combination
Scientific Rationale

BIFIACNEL® is a probiotic supplement specifically formulated to target acne-related skin conditions. It includes two strains selected for their potent anti-inflammatory properties:

  • Ligilactobacillus salivarius LS03: Chosen from over 70 strains for its superior anti-inflammatory activity, particularly in IL-10 production. LS03 excels in reducing IL-8, thereby curbing local inflammation induced by Propionibacterium acnes (P. acnes). A standout feature of LS03 is its production of bacteriocins, which are effective against P. acnes [1].

  • Bifidobacterium breve BR03: Recognized as the most potent anti-inflammatory Bifidobacterium in Probiotical’s collection, largely due to its IL-10 production [2,3]. This effect is also strongly induced by Lactobacillus casei LC03 [4].

BIFIACNEL®'s efficacy was evaluated in a randomized, placebo and active controlled clinical study involving patients suffering from mild to moderate acne [5]. The results from 8 weeks of supplementation with BIFIACNEL® demonstrated significant improvements in several aspects:

  • Reduction in the total number of facial lesions.

  • Decrease in erythema and desquamation.

  • Lowered sebum secretion rate.

  • Reduced presence of P. acnes on the skin while promoting the growth of beneficial Staphylococcus epidermidis.


1. Deidda F, et al. New Approach in Acne Therapy: A Specific Bacteriocin Activity and a Targeted Anti IL-8 Property in Just 1 Probiotic Strain, the L. salivarius LS03. J Clin Gastroenterol. 2018 Nov/Dec;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017:S78-S81. doi: 10.1097/MCG.0000000000001053.

2. Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019;  7:214. Doi: 10.35248/2329-8901.19.7.214.

3. Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.

4. Internal Probiotical data

5. Rinaldi F. et al. Facial Acne: A Randomized, Double-Blind, Placebo-Controlled Study on the Clinical Efficacy of a Symbiotic Dietary Supplement. Dermatol Ther (Heidelb). 2022 Feb;12(2):577-589. doi: 10.1007/s13555-021-00664-z.